Cardiovascular Risk in Systemic Autoimmune Diseases: Epigenetic Mechanisms of Immune Regulatory Functions
Open Access
- 14 September 2011
- journal article
- review article
- Published by Hindawi Limited in Clinical and Developmental Immunology
- Vol. 2012, 1-10
- https://doi.org/10.1155/2012/974648
Abstract
Autoimmune diseases (AIDs) have been associated with accelerated atherosclerosis (AT) leading to increased cardio- and cerebrovascular disease risk. Traditional risk factors, as well as systemic inflammation mediators, including cytokines, chemokines, proteases, autoantibodies, adhesion receptors, and others, have been implicated in the development of these vascular pathologies. Yet, the characteristics of vasculopathies may significantly differ depending on the underlying disease. In recent years, many new genes and signalling pathways involved in autoimmunity with often overlapping patterns between different disease entities have been further detected. Epigenetics, the control of gene packaging and expression independent of alterations in the DNA sequence, is providing new directions linking genetics and environmental factors. Epigenetic regulatory mechanisms comprise DNA methylation, histone modifications, and microRNA activity, all of which act upon gene and protein expression levels. Recent findings have contributed to our understanding of how epigenetic modifications could influence AID development, not only showing differences between AID patients and healthy controls, but also showing how one disease differs from another and even how the expression of key proteins involved in the development of each disease is regulated.Keywords
Funding Information
- Junta de Andalucía (0246/2009, P08-CVI-04234, PS09/01809)
This publication has 96 references indexed in Scilit:
- MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndromeArthritis & Rheumatism, 2011
- MicroRNAs in Sjögren's syndrome as a prototypic autoimmune diseaseAutoimmunity Reviews, 2010
- MicroRNAs as biomarkers in rheumatic diseasesNature Reviews Rheumatology, 2010
- Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: Is microRNA‐146 all we need?Arthritis & Rheumatism, 2009
- miRiad Roles for the miR-17-92 Cluster in Development and DiseaseCell, 2008
- Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritisArthritis & Rheumatism, 2008
- Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytesNature Immunology, 2008
- Atherosclerosis and systemic lupus erythematosus — mechanistic basis of the associationCurrent Opinion in Immunology, 2007
- Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cellsNature Cell Biology, 2007
- Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupusProceedings of the National Academy of Sciences, 2007